Safety and tolerability of intranasal insulin in Parkinson's disease.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

BackgroundRepurposing therapeutic treatments for diabetes may be a promising strategy for the treatment of neurodegenerative disorders. Intranasal insulin (INI) is shown to improve memory, attention, and cognition in Alzheimer's dementia. Associations between the etiology of Parkinson's Disease (PD), brain glucose hypometabolism, and central insulin resistance suggest INI as a promising treatment for PD.MethodsA phase II single center, randomized, double-blind clinical trial was conducted in 30 participants with PD, aged 41-89, MoCA ≥ 16, on a stable dose of anti-PD medications. Participants were randomized to receive intranasal treatment for 21 days with either placebo, or 20, 40, or 80 IU of regular insulin (INI) using SipNose intranasal device. Primary outcomes of safety and tolerability were assessed in 30 participants by monitoring hypoglycemia, weight, and adverse events. Cognitive, mood, and motor measures were collected pre- and post-treatment for secondary outcome analysis and assessed in 28 participants.ResultsNo significant changes in weight or serum insulin were observed during the study. No hypoglycemic values (ConclusionINI exhibits an acceptable safety profile in patients with PD. Further studies to investigate if INI has a positive impact on cognitive and motor symptoms in PD are warranted.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT04251585 Identifier, NCT04251585.

İlgili konular